Skip to content
HowShorted

Axsome Therapeutics, Inc. short interest in 2018

In 2018, Axsome Therapeutics, Inc.'s disclosed short interest ran from 3.25% of shares outstanding on 12 Jan 2018 to 3.63% on 31 Dec 2018, a change of +0.38 percentage points. The year's high was 7.08% on 29 Jun 2018 and its low 2.22% on 13 Apr 2018, averaging 4.12% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.43 days on 13 Jul 2018. Full history: Axsome Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Axsome Therapeutics, Inc. in 2018

2018 in figures

Start of year
3.25% (12 Jan 2018)
End of year
3.63% (31 Dec 2018)
Change
+0.38 pp
High
7.08% (29 Jun 2018)
Low
2.22% (13 Apr 2018)
Average
4.12%
Highest days to cover
25.43 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

Axsome Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20183.25%1.00
31 Jan 20184.01%1.97
15 Feb 20183.98%4.83
28 Feb 20183.77%4.21
15 Mar 20183.37%4.1210-K filed, results (8-K)
29 Mar 20183.05%4.23
13 Apr 20182.22%3.67
30 Apr 20182.44%2.63
15 May 20182.81%3.5410-Q filed, results (8-K)
31 May 20182.96%8.61
15 Jun 20183.48%4.45
29 Jun 20187.08%7.60
13 Jul 20187.01%25.43
31 Jul 20186.14%9.71
15 Aug 20185.69%13.2810-Q filed, results (8-K)
31 Aug 20185.39%9.80
14 Sep 20185.46%12.65
28 Sep 20185.64%11.28
15 Oct 20183.37%2.46
31 Oct 20184.69%2.75
15 Nov 20182.95%3.3210-Q filed, results (8-K)
30 Nov 20183.57%9.14
14 Dec 20182.99%2.09
31 Dec 20183.63%2.95

See also: Axsome Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.